Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment

Rachael Zemek, Emma de Jong, Melvin Chin, Iona Schuster, Vanessa Fear, Tom Casey, Catherine Forbes, Sarah Dart, Connull Leslie, Ayham Zaitouny, Michael Small, Louis Boon, Alistair R. R. Forrest, Daithi O Muiri, Mariapia Degli-Esposti, Michael Millward, Anna Nowak, Timo Lassmann, Anthony Bosco, Richard Lake & 1 others Willem Lesterhuis

Research output: Contribution to journalArticle

4 Citations (Scopus)
279 Downloads (Pure)

Abstract

Cancer immunotherapy using antibodies that target immune checkpoints has delivered outstanding results. However, responses only occur in a subset of patients, and it is not fully understood what biological processes determine an effective outcome. This lack of understanding hinders the development of rational combination treatments. We set out to define the pretreatment microenvironment associated with an effective outcome by using the fact that inbred mouse strains bearing monoclonal cancer cell line–derived tumors respond in a dichotomous manner to immune checkpoint blockade (ICB). We compared the cellular composition and gene expression profiles of responsive and nonresponsive tumors from mice before ICB and validated the findings in cohorts of patients with cancer treated with ICB antibodies. We found that responsive tumors were characterized by an inflammatory gene expression signature consistent with up-regulation of signal transducer and activator of transcription 1 (STAT1) and Toll-like receptor 3 (TLR3) signaling and down-regulation of interleukin-10 (IL-10) signaling. In addition, responsive tumors had more infiltrating-activated natural killer (NK) cells, which were necessary for response. Pretreatment of mice with large established tumors using the STAT1-activating cytokine interferon-γ (IFNγ), the TLR3 ligand poly(I:C), and an anti–IL-10 antibody sensitized tumors to ICB by attracting IFNγ-producing NK cells into the tumor, resulting in increased cure rates. Our results identify a pretreatment tumor microenvironment that predicts response to ICB, which can be therapeutically attained. These data suggest a biomarker-driven approach to patient management to establish whether a patient would benefit from treatment with sensitizing therapeutics before ICB.
Original languageEnglish
Article numbereaav7816
Number of pages14
JournalScience Translational Medicine
Volume11
Issue number501
DOIs
Publication statusPublished - 17 Jul 2019

Fingerprint

STAT1 Transcription Factor
Tumor Microenvironment
Neoplasms
Toll-Like Receptor 3
Transcriptome
Natural Killer Cells
Interferons
Neoplasm Antibodies
Biological Phenomena
Inbred Strains Mice
Antibodies
Interleukin-10
Immunotherapy
Up-Regulation
Therapeutics
Down-Regulation
Biomarkers
Cytokines
Ligands

Cite this

Zemek, Rachael ; de Jong, Emma ; Chin, Melvin ; Schuster, Iona ; Fear, Vanessa ; Casey, Tom ; Forbes, Catherine ; Dart, Sarah ; Leslie, Connull ; Zaitouny, Ayham ; Small, Michael ; Boon, Louis ; Forrest, Alistair R. R. ; O Muiri, Daithi ; Degli-Esposti, Mariapia ; Millward, Michael ; Nowak, Anna ; Lassmann, Timo ; Bosco, Anthony ; Lake, Richard ; Lesterhuis, Willem. / Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. In: Science Translational Medicine. 2019 ; Vol. 11, No. 501.
@article{60715316af4d46af8c9f68472aa2d195,
title = "Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment",
abstract = "Cancer immunotherapy using antibodies that target immune checkpoints has delivered outstanding results. However, responses only occur in a subset of patients, and it is not fully understood what biological processes determine an effective outcome. This lack of understanding hinders the development of rational combination treatments. We set out to define the pretreatment microenvironment associated with an effective outcome by using the fact that inbred mouse strains bearing monoclonal cancer cell line–derived tumors respond in a dichotomous manner to immune checkpoint blockade (ICB). We compared the cellular composition and gene expression profiles of responsive and nonresponsive tumors from mice before ICB and validated the findings in cohorts of patients with cancer treated with ICB antibodies. We found that responsive tumors were characterized by an inflammatory gene expression signature consistent with up-regulation of signal transducer and activator of transcription 1 (STAT1) and Toll-like receptor 3 (TLR3) signaling and down-regulation of interleukin-10 (IL-10) signaling. In addition, responsive tumors had more infiltrating-activated natural killer (NK) cells, which were necessary for response. Pretreatment of mice with large established tumors using the STAT1-activating cytokine interferon-γ (IFNγ), the TLR3 ligand poly(I:C), and an anti–IL-10 antibody sensitized tumors to ICB by attracting IFNγ-producing NK cells into the tumor, resulting in increased cure rates. Our results identify a pretreatment tumor microenvironment that predicts response to ICB, which can be therapeutically attained. These data suggest a biomarker-driven approach to patient management to establish whether a patient would benefit from treatment with sensitizing therapeutics before ICB.",
author = "Rachael Zemek and {de Jong}, Emma and Melvin Chin and Iona Schuster and Vanessa Fear and Tom Casey and Catherine Forbes and Sarah Dart and Connull Leslie and Ayham Zaitouny and Michael Small and Louis Boon and Forrest, {Alistair R. R.} and {O Muiri}, Daithi and Mariapia Degli-Esposti and Michael Millward and Anna Nowak and Timo Lassmann and Anthony Bosco and Richard Lake and Willem Lesterhuis",
year = "2019",
month = "7",
day = "17",
doi = "10.1126/scitranslmed.aav7816",
language = "English",
volume = "11",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "AMER ASSOC ADVANCEMENT SCIENCE",
number = "501",

}

Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. / Zemek, Rachael; de Jong, Emma; Chin, Melvin; Schuster, Iona; Fear, Vanessa; Casey, Tom; Forbes, Catherine; Dart, Sarah; Leslie, Connull; Zaitouny, Ayham; Small, Michael; Boon, Louis ; Forrest, Alistair R. R.; O Muiri, Daithi; Degli-Esposti, Mariapia; Millward, Michael; Nowak, Anna; Lassmann, Timo; Bosco, Anthony; Lake, Richard; Lesterhuis, Willem.

In: Science Translational Medicine, Vol. 11, No. 501, eaav7816, 17.07.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment

AU - Zemek, Rachael

AU - de Jong, Emma

AU - Chin, Melvin

AU - Schuster, Iona

AU - Fear, Vanessa

AU - Casey, Tom

AU - Forbes, Catherine

AU - Dart, Sarah

AU - Leslie, Connull

AU - Zaitouny, Ayham

AU - Small, Michael

AU - Boon, Louis

AU - Forrest, Alistair R. R.

AU - O Muiri, Daithi

AU - Degli-Esposti, Mariapia

AU - Millward, Michael

AU - Nowak, Anna

AU - Lassmann, Timo

AU - Bosco, Anthony

AU - Lake, Richard

AU - Lesterhuis, Willem

PY - 2019/7/17

Y1 - 2019/7/17

N2 - Cancer immunotherapy using antibodies that target immune checkpoints has delivered outstanding results. However, responses only occur in a subset of patients, and it is not fully understood what biological processes determine an effective outcome. This lack of understanding hinders the development of rational combination treatments. We set out to define the pretreatment microenvironment associated with an effective outcome by using the fact that inbred mouse strains bearing monoclonal cancer cell line–derived tumors respond in a dichotomous manner to immune checkpoint blockade (ICB). We compared the cellular composition and gene expression profiles of responsive and nonresponsive tumors from mice before ICB and validated the findings in cohorts of patients with cancer treated with ICB antibodies. We found that responsive tumors were characterized by an inflammatory gene expression signature consistent with up-regulation of signal transducer and activator of transcription 1 (STAT1) and Toll-like receptor 3 (TLR3) signaling and down-regulation of interleukin-10 (IL-10) signaling. In addition, responsive tumors had more infiltrating-activated natural killer (NK) cells, which were necessary for response. Pretreatment of mice with large established tumors using the STAT1-activating cytokine interferon-γ (IFNγ), the TLR3 ligand poly(I:C), and an anti–IL-10 antibody sensitized tumors to ICB by attracting IFNγ-producing NK cells into the tumor, resulting in increased cure rates. Our results identify a pretreatment tumor microenvironment that predicts response to ICB, which can be therapeutically attained. These data suggest a biomarker-driven approach to patient management to establish whether a patient would benefit from treatment with sensitizing therapeutics before ICB.

AB - Cancer immunotherapy using antibodies that target immune checkpoints has delivered outstanding results. However, responses only occur in a subset of patients, and it is not fully understood what biological processes determine an effective outcome. This lack of understanding hinders the development of rational combination treatments. We set out to define the pretreatment microenvironment associated with an effective outcome by using the fact that inbred mouse strains bearing monoclonal cancer cell line–derived tumors respond in a dichotomous manner to immune checkpoint blockade (ICB). We compared the cellular composition and gene expression profiles of responsive and nonresponsive tumors from mice before ICB and validated the findings in cohorts of patients with cancer treated with ICB antibodies. We found that responsive tumors were characterized by an inflammatory gene expression signature consistent with up-regulation of signal transducer and activator of transcription 1 (STAT1) and Toll-like receptor 3 (TLR3) signaling and down-regulation of interleukin-10 (IL-10) signaling. In addition, responsive tumors had more infiltrating-activated natural killer (NK) cells, which were necessary for response. Pretreatment of mice with large established tumors using the STAT1-activating cytokine interferon-γ (IFNγ), the TLR3 ligand poly(I:C), and an anti–IL-10 antibody sensitized tumors to ICB by attracting IFNγ-producing NK cells into the tumor, resulting in increased cure rates. Our results identify a pretreatment tumor microenvironment that predicts response to ICB, which can be therapeutically attained. These data suggest a biomarker-driven approach to patient management to establish whether a patient would benefit from treatment with sensitizing therapeutics before ICB.

UR - http://stm.sciencemag.org/cgi/content/full/11/501/eaav7816?ijkey=N4yDIc0qTrYKE&keytype=ref&siteid=scitransmed

U2 - 10.1126/scitranslmed.aav7816

DO - 10.1126/scitranslmed.aav7816

M3 - Article

VL - 11

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 501

M1 - eaav7816

ER -